Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics has demonstrated consistent growth in EsoGuard test volumes, with a year-over-year increase to 2,841 tests in Q3 2025, suggesting a solid demand for their diagnostic solutions. The company is poised for rapid revenue growth as it expands insurance coverage, particularly anticipating positive impacts from Medicare coverage and other payer sources in the second half of 2025. Additionally, a favorable Medicare coverage decision follows a successful MolDX CAC meeting, indicating potential for increased patient access and market expansion, thus enhancing Lucid Diagnostics' financial prospects.

Bears say

Lucid Diagnostics Inc. reported revenues in 3Q25 that fell short of consensus expectations, indicating challenges in customer adoption and market penetration of its EsoGuard product. The company recorded a pro forma net loss of $10.3 million, slightly worse than anticipated, alongside ongoing balance sheet and liquidity risks that could hinder future growth. Additionally, a decline in the number of EsoGuard tests processed, coupled with potential reimbursement issues and increasing competition, heightens uncertainties surrounding its operational and financial viability.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Mar 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.